

MipTec 2010

Round Table Discussion: "Open Innovation"

Accelerating Innovation in drug discovery through partnerships between Academia and Industry

Date: Thursday, September 23, 2010

Time: 15:30 to 18:00

Location: Lecture Hall G

The pharmaceutical industry has long operated on a fully integrated business model in R&D:

All core competencies had been developed and kept in-house to prevent the distribution of knowledge and IP and thus assure the competitive advantage - outsourcing was not favored.

Developing new drugs on its own and retaining exclusive IP was an economical very successful model for Big Pharma, until R&D productivity was going down noticeably. Even though spending on research has increased significantly over the past decade, the number of new chemical entities per year has remained almost the same.

The closed innovation model turns out to be unsustainable. The pharmaceutical industry realizes that it needs to transform its R&D operation and find more efficient ways to innovate. At the same time academic biomedical research institutions are recognizing the benefits of potential partnerships with big pharma: that there are tools, technologies, experience and financial resources within pharmaceutical companies that can help academic researchers to translate their ideas and research into drugs.

The round table will bring together representatives from large pharma companies, academic institutions and bridging organizations to discuss "Open Innovation" in drug discovery - new ways to partner in a more collaborative mode - expectations, concerns and opportunities. Various strategies to increase innovation in Drug Discovery will be introduced.

Academic representatives:

Bill Janzen, The University of North Carolina at Chapel Hill, USA

Prof Jörg Kistler, Director, School of Biological Sciences, The University of Auckland, NZ

Bert Klebl, LDC-Dortmund / MPI, Germany

Initiatives/Bridging Organizations:

Phil Gribbon, European ScreeningPort, Germany

Tim Hammonds, Cancer Research Technology (CRT), UK

Jens-Peter von Kries, Leibniz-Inst. für Molek. Pharmakologie (FMP), Germany / EU-Openscreen

Prof. Dr. Guus van Dongen, VU University Medical Center, Amsterdam, Netherlands / EATRIS

Industry representatives:

Hubert Haag, Sanofi-Aventis, Germany

Jeremy Everett, University of Greenwich and at Imperial College London, UK

Sabrina Corazza, Axxam, Italy

Matthias Gottwald, Bayer Schering Pharma AG, Germany

Session Sponsor:

sanofi-aventis: www.sanofi-aventis.de

c.a.r.u.s. AG: The c.a.r.u.s. group focuses on designing, implementing and providing service for high-performance IT solutions. With the browser based IT platform ViSoR (Virtual Screening optimizing the Reality), c.a.r.u.s. is offering a highly innovative and worldwide unique workplace for knowledge management within the context of pharmaceutical drug development. For more information please visit www.carus-it.com

Organizers:

Phil Gribbon, European ScreeningPort (Chair)

Mira Grättinger, European ScreeningPort (Organizer)

Hubert Haag, Sanofi-Aventis (Co-Organizer)

Marc Bickle, MPI Dresden (Co-Organizer)